Answers are grounded in this paper and cite their sources.
Ki-67 is a marker of tumor proliferation with potential value for risk stratification and personalized management in rectal cancer. However, conventional immunohistochemical assessment requires tissue sampling and may be affected by intra-tumoral heterogeneity. MRI-based radiomics offer non-invasive approaches for predicting Ki-67 expression. This systematic review and meta-analysis evaluated its diagnostic performance. This review followed PRISMA 2020 and searched PubMed, Scopus, Embase, and Web of Science through August 30, 2026. Studies evaluating radiomics or deep learning models based on pretreatment MRI for predicting Ki-67 expression in rectal cancer were included. Methodological quality was assessed using QUADAS-2 and the Radiomics Quality Score. Training and validation cohorts were analyzed separately. For radiomics studies providing 2 × 2 data, sensitivity and specificity were pooled using a bivariate random-effects model; positive and negative likelihood ratios, diagnostic odds ratios, and summary receiver operating characteristic curve areas were also calculated. Because only four studies were eligible for quantitative synthesis, the pooled analyses were considered exploratory. Out of 8218 records, 5 retrospective studies comprising 1585 rectal cancer patients were included. Four studies used radiomics, and one was based on a deep learning pipeline. An exploratory quantitative synthesis of four radiomics studies yielded a validation sensitivity of 0.85 (95% CI, 0.80–0.89), specificity of 0.60 (95% CI, 0.40–0.77), and SROC AUC of 0.842. The deep learning study reported AUCs of 0.97 and 0.98 in its training and validation sets; however, these figures require caution as this single study carries a high risk of bias, suggesting potential overfitting rather than clinical superiority. Methodological quality was limited, with a mean RQS score of 16.25/36 and a notable risk of bias in the deep learning study. Radiomics models applied to preoperative MRI yielded exploratory diagnostic estimates for the non-invasive prediction of Ki-67 expression in rectal cancer. Deep-learning findings were limited to non-comparable descriptive observations and do not establish superiority over radiomics. Because the available evidence is retrospective and methodologically limited, and no study evaluated effects on clinical decisions or patient outcomes, further prospective external validation is required before clinical application.
No takes yet. Share an insight, caveat, or question.
Rahnama et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: